Human Reproduction, Vol. 15, No. 1, 29-35,
January 2000
© 2000 European Society of Human Reproduction and Embryology
Increasing the daily dose of recombinant follicle stimulating hormone (Puregon®) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation
1 Organon Laboratories Ltd, Science Park, CB4 0FL Cambridge, UK, 2 University Hospital Nijmegen, Department of Obstetrics and Gynaecology, Geert Grooteplein Zuid 16, 6525 GA Nijmegen, The Netherlands, 3 Hacettepe University, Faculty of Medicine, Department of Obstetrics and Gynaecology, Division of Reproductive Endocrinology & Infertility and 4 Zekai Tahir Burak, Teaching and Research Hospital, Ankara, Turkey, 5 Equipo IVI Madrid, C/Santiago de Compostela, 88–Bajo, 28035 Madrid and 6 Department of Obstetrics and Gynaecology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, C/Casanova 143, 08036, Barcelona, Spain and 7 Institut d'Endocrinologie, Médicine la Reproduction, 6, rue Rocca 13, 147 Marseille Cedex 08, France
A prospective, randomized, double-blind, multicentre (n = 6) study was conducted to compare the influence of either a 150 or 250 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH, Puregon®) on the number of oocytes retrieved and the total dose used in down-regulated women between 30 and 39 years of age undergoing ovarian stimulation. In all, 138 women were treated with recombinant FSH, 67 with 150 IU and 71 with 250 IU. The number of oocytes retrieved in the low-dose group was 9.1 compared to 10.6 in the high-dose group (not significant). In the 30–33 years of age class receiving the 250 IU dose, a surplus of 4.2 oocytes (14.8 versus 10.6) was found, whereas in the 37–39 age class nearly one oocyte more was retrieved in the 150 IU group (8.1 versus 7.4). The total dose used to reach the criterion for human chorionic gonadotrophin (HCG) administration was 1727 IU for the women treated with 150 IU daily and 2701 IU for the 250 IU treated women (P < 0.001). No significant relationships were found between serum FSH concentrations as obtained in the early follicular phase and the number of oocytes collected, or the total dose. It is concluded that in women between 30 and 39 years of age, the decline in number of oocytes retrieved with increasing age cannot be overcome by augmenting the daily dose of recombinant FSH from 150 to 250 IU.
Key words: age/IVF/Puregon/recombinant FSH/trial
8 To whom correspondence should be addressed at:e-mail h.out{at}organon.cge.akzonobel.nl
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M.F.G. Verberg, N.S. Macklon, G. Nargund, R. Frydman, P. Devroey, F.J. Broekmans, and B.C.J.M. Fauser Mild ovarian stimulation for IVF Hum. Reprod. Update, January 1, 2009; 15(1): 13 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fleming, N. Deshpande, I. Traynor, and R.W.S. Yates Dynamics of FSH-induced follicular growth in subfertile women: relationship with age, insulin resistance, oocyte yield and anti-Mullerian hormone Hum. Reprod., June 1, 2006; 21(6): 1436 - 1441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization Endocr. Rev., April 1, 2006; 27(2): 170 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.R. Klinkert, F.J.M. Broekmans, C.W.N. Looman, J.D.F. Habbema, and E.R. te Velde Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial Hum. Reprod., March 1, 2005; 20(3): 611 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. Inge, P. R. Brinsden, and K. T. Elder Oocyte number per live birth in IVF: were Steptoe and Edwards less wasteful? Hum. Reprod., March 1, 2005; 20(3): 588 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Klinkert, E. te Velde, and F. Broekmans 'Defining poor ovarian response during IVF cycles, in women aged <40 years, and its relationship with treatment outcome' Hum. Reprod., February 1, 2005; 20(2): 573 - 573. [Full Text] [PDF]
|
|
|
|
|
|
J. Kwee, R. Schats, J. McDonnell, C.B. Lambalk, and J. Schoemaker Intercycle variability of ovarian reserve tests: results of a prospective randomized study Hum. Reprod., March 1, 2004; 19(3): 590 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Popovic-Todorovic, A. Loft, H.E. Bredkjaeer, S. Bangsboll, I.K. Nielsen, and A.N. Andersen A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment Hum. Reprod., November 1, 2003; 18(11): 2275 - 2282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kwee, M.W. Elting, R. Schats, P.D. Bezemer, C.B. Lambalk, and J. Schoemaker Comparison of endocrine tests with respect to their predictive value on the outcome of ovarian hyperstimulation in IVF treatment: results of a prospective randomized study Hum. Reprod., July 1, 2003; 18(7): 1422 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Popovic-Todorovic, A. Loft, A. Lindhard, S. Bangsboll, A.M. Andersson, and A.N. Andersen A prospective study of predictive factors of ovarian response in 'standard' IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram Hum. Reprod., April 1, 2003; 18(4): 781 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.L. Luborsky, P. Thiruppathi, B. Rivnay, R. Roussev, C. Coulam, and E. Radwanska Evidence for different aetiologies of low estradiol response to FSH: age-related accelerated luteinization of follicles or presence of ovarian autoantibodies Hum. Reprod., October 1, 2002; 17(10): 2641 - 2649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. El-Toukhy, Y. Khalaf, R. Hart, A. Taylor, and P. Braude Young age does not protect against the adverse effects of reduced ovarian reserve--an eight year study Hum. Reprod., June 1, 2002; 17(6): 1519 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Nikolaou, S. Lavery, C. Turner, R. Margara, and G. Trew Is there a link between an extremely poor response to ovarian hyperstimulation and early ovarian failure? Hum. Reprod., April 1, 2002; 17(4): 1106 - 1111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sykes, H. J. Out, S. J. Palmer, and J. v. Loon The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments Hum. Reprod., December 1, 2001; 16(12): 2557 - 2562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wikland, C. Bergh, K. Borg, T. Hillensjo, C.M. Howles, A. Knutsson, L. Nilsson, and M. Wood A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI Hum. Reprod., August 1, 2001; 16(8): 1676 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Out, I. David, R. Ron-El, S. Friedler, E. Shalev, J. Geslevich, J. Dor, A. Shulman, Z. Ben-Rafael, B. Fisch, et al. A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles Hum. Reprod., June 1, 2001; 16(6): 1104 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Strandell, A. Lindhard, U. Waldenstrom, and J. Thorburn Prophylactic salpingectomy does not impair the ovarian response in IVF treatment Hum. Reprod., June 1, 2001; 16(6): 1135 - 1139. [Abstract] [Full Text] [PDF]
|
|